164,557 Thermo Fisher Scientific Inc. $TMO Shares Bought by International Assets Investment Management LLC

Key Points

• International Assets Investment Management increased its Thermo Fisher stake by 164,557 shares, or 3,023.3%, to 170,000 shares valued at about $114.8 million.
• Institutional investors own 89.23% of the company, while analysts’ consensus rating is “Moderate Buy,” with an average price target of $683.64.
• Thermo Fisher beat quarterly estimates, reporting EPS of $6.68 versus $6.40 expected and revenue of $12.14 billion, up 9.1% year over year. Insiders, meanwhile, sold 50,046 shares worth about $30.8 million over the past three months.

International Assets Investment Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3,023.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 170,000 shares of the medical research company's stock after purchasing an additional 164,557 shares during the period. Thermo Fisher Scientific comprises approximately 1.8% of International Assets Investment Management LLC's holdings, making the stock its 4th largest holding. International Assets Investment Management LLC's holdings in Thermo Fisher Scientific were worth $114,758,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth about $15,501,867,000. Corient Private Wealth LP purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $382,547,000. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $1,974,561,000. Bank of America Corp DE bought a new position in Thermo Fisher Scientific in the 2nd quarter worth about $1,952,930,000. Finally, Legal & General Group Plc purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $1,122,351,000. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, VP Lisa Britt sold 11,440 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Shafer sold 25,500 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 50,046 shares of company stock valued at $30,779,192. Corporate insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Barclays boosted their price target on Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an "overweight" rating in a report on Thursday, October 22nd. Citigroup raised their price objective on Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a "buy" rating in a report on Friday, October 23rd. Leerink Partners lifted their target price on Thermo Fisher Scientific from $600.00 to $620.00 and gave the company an "outperform" rating in a research report on Wednesday, July 22nd. Guggenheim initiated coverage on Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a "buy" rating and a $740.00 target price for the company. Finally, Rothschild & Co Redburn increased their price target on Thermo Fisher Scientific from $725.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $683.64.

Thermo Fisher Scientific Stock Up 2.7%

Shares of TMO traded up $17.99 during mid-day trading on Friday, hitting $694.93. The company's stock had a trading volume of 2,090,723 shares, compared to its average volume of 2,372,406. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The company's 50-day moving average is $661.03 and its 200-day moving average is $554.78. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $712.17. The firm has a market capitalization of $257.48 billion, a price-to-earnings ratio of 36.65, a PEG ratio of 2.78 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. The company had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. Thermo Fisher Scientific's revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company posted $5.79 earnings per share. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.92%.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing the prior authorization, which had $1 billion remaining. The program has no expiration date and could support per-share results and signal confidence in the business. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
• Positive Sentiment: Recent quarterly results were better than expected: EPS of $6.68 beat the $6.40 consensus, while revenue of $12.14 billion exceeded estimates and increased 9.1% year over year. Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
• Positive Sentiment: Thermo Fisher declared a quarterly dividend of $0.47 per share, payable January 15, 2027. The annualized dividend is $1.88 per share, though the indicated yield is modest at about 0.3%. Thermo Fisher Scientific Announces Quarterly Dividend
• Positive Sentiment: The company introduced value-priced AmpSure qPCR master mixes, adding an offering aimed at labs seeking dependable testing performance at lower cost. Thermo Fisher Introduces AmpSure Universal qPCR Master Mixes
• Neutral Sentiment: Market research reports point to growth in oligonucleotide synthesis, mRNA manufacturing, protein labeling and Q-TOF mass spectrometry—areas related to Thermo Fisher’s markets. These industry forecasts suggest potential demand tailwinds, but do not provide company-specific sales or earnings guidance. Global Oligonucleotide Synthesis Services Market Report 2026

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.

The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.